结核/HIV共感染儿童接受洛匹那韦/利托那韦二线抗反转录病毒治疗时利福布汀的药代动力学与安全性
本研究在15例3-15岁结核/HIV共感染儿童中评估利福布汀2.5 mg/kg每日联合标准剂量洛匹那韦/利托那韦的药代动力学与安全性。中位利福布汀AUC0-24为5.21 μg·h/mL,与成人相当;严重中性粒细胞减少相对少见且继续用药可改善。数据支持该人群使用利福布汀。
要点
- 利福布汀2.5 mg/kg每日联合洛匹那韦/利托那韦在中位13.1岁儿童中AUC0-24与成人相当。
- 3-4级中性粒细胞减少少见,未中断治疗且无临床后遗症。
- 第2周有4例AUC0-24低于3.8 μg·h/mL,第4、8周均高于该值。
核心结论
- 利福布汀2.5 mg/kg每日在需洛匹那韦/利托那韦的结核/HIV共感染儿童中达到与成人相当的AUC0-24,HIV和结核治疗结局良好。
- 严重中性粒细胞减少相对少见,且继续利福布汀治疗后可改善。
研究设计与样本
- 评估利福布汀安全性与血浆药代动力学的研究,纳入15例3-15岁接受利福布汀2.5 mg/kg每日联合标准剂量洛匹那韦/利托那韦的结核/HIV共感染儿童。
- 采用密集采样和非房室分析描述利福布汀起始后第2、4、8周的AUC0-24,并在研究期间12次访视中密集监测临床和实验室毒性。
主要发现
- 15例儿童中位(IQR)年龄13.1(10.9-14.0)岁,体重25.5(22.3-30.5)kg。
- 中位(IQR)利福布汀AUC0-24为5.21(4.38-6.60)μg·h/mL。
- 第2周有4例AUC0-24低于3.8 μg·h/mL(人群平均暴露目标),第4、8周所有患者AUC0-24均高于3.8 μg·h/mL。
- 利福布汀治疗期间506次实验室评估中,3级和4级异常分别发生16次(3%)和2次(0.4%),涉及9例(60%)儿童。
- 3级(n=4)和4级(n=1)中性粒细胞减少均未中断治疗即缓解,无临床后遗症;1例儿童在第4周死于HIV相关并发症。
关键数值与推荐
- 利福布汀AUC0-24目标为3.8 μg·h/mL(人群平均暴露目标)。
- 利福布汀剂量为2.5 mg/kg每日,联合标准剂量洛匹那韦/利托那韦。
临床怎么用
- 对于需洛匹那韦/利托那韦二线抗反转录病毒治疗的结核/HIV共感染儿童,可考虑使用利福布汀2.5 mg/kg每日。
- 治疗期间应监测中性粒细胞计数,但严重中性粒细胞减少并非必须中断利福布汀的指征。
局限性
- 样本量小(15例),结果需更大规模研究验证。
- 单臂设计,无对照组。
- 1例儿童死亡与HIV相关并发症有关,可能影响安全性解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options are limited for TB/HIV-coinfected children who require PI-based ART. Rifabutin is the preferred rifamycin for adults on PIs, but the one study evaluating rifabutin with PIs among children was stopped early due to severe neutropenia. METHODS: We evaluated rifabutin safety and plasma pharmacokinetics among coinfected children 3-15 years of age receiving rifabutin 2.5 mg/kg daily with standard doses of lopinavir/ritonavir. The AUC0-24 at 2, 4 and 8 weeks after rifabutin initiation was described using intensive sampling and non-compartmental analysis. Clinical and laboratory toxicities were intensively monitored at 12 visits throughout the study. RESULTS: Among 15 children with median (IQR) age 13.1 (10.9-14.0) years and weight 25.5 (22.3-30.5) kg, the median (IQR) rifabutin AUC0-24 was 5.21 (4.38-6.60) μg·h/mL. Four participants had AUC0-24 below 3.8 μg·h/mL (a target for the population average exposure) at week 2 and all had AUC0-24 higher than 3.8 μg·h/mL at the 4 and 8 week visits. Of 506 laboratory evaluations during rifabutin, grade 3 and grade 4 abnormalities occurred in 16 (3%) and 2 (0.4%) instances, respectively, involving 9 (60%) children. Specifically, grade 3 (n = 4) and grade 4 (n = 1) neutropenia resolved without treatment interruption or clinical sequelae in all patients. One child died at week 4 of HIV-related complications. CONCLUSIONS: In children, rifabutin 2.5 mg/kg daily achieved AUC0-24 comparable to adults and favourable HIV and TB treatment outcomes were observed. Severe neutropenia was relatively uncommon and improved with ongoing rifabutin therapy. These data support the use of rifabutin for TB/HIV-coinfected children who require lopinavir/ritonavir.
引用
- Rawizza HE, Oladokun R, Ejeliogu E, et al. Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. J Antimicrob Chemother. 2021. PMID: 33294914. doi:10.1093/jac/dkaa512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。